Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. The global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 did not meet its primary endpoint.